(News Bulletin 247) – Cellectis presented several sets of preclinical data at the 29th International Society for Cell & Gene Therapy (ISCT) event which took place in Paris in recent days.
Preclinical data on UCART20x22, Cellectis’ first allogeneic dual CAR T-cell product candidate for the treatment of B-cell malignancies, has been presented.
Overall, Cellectis has provided preclinical proof-of-concept data for a first dual allogeneic CAR T cell to overcome current resistance mechanisms in B-NHL, while offering a potential therapeutic alternative to CD19 targeting.
‘Encouraging’ data on the gene editing process using Cellectis TALEN technology to ‘develop a highly efficient HBB gene correction of the sickle cell mutation’, was also presented.
“We remain focused on developing our product candidates to deliver breakthrough treatments that could benefit thousands of patients worldwide,” said André Choulika, Ph.D., Chief Executive Officer of Cellectis.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
